Advancing the Science

Mayo Clinic Medical Science Blog

Share this:
March 31, 2016

Although Prostate-specific Antigen Screenings Now Result in Fewer Biopsies, Relative Risk of Complications has Increased

By Elizabeth Zimmermann

mss_522405While absolute rates of biopsy and post-biopsy complications have decreased following several benchmark prostate-specific antigen (PSA) screening publications, the relative risk for each patient continues to increase, according to a new study by Mayo Clinic researchers.

The study is the largest to examine the impact of PSA screening trials and revised PSA screening guidelines on rates of prostate biopsy and the first to examine their impact on post-biopsy complications. The results, which appear in European Urology, suggest a need to reduce the harm associated with biopsy.

Read the full news release.


Tags: Boris Gershman, Choose Wisely, Findings, Jeffrey Karnes, Kern Center, OtumLabs, prostate cancer, prostate cancer biopsy, prostate-specific antigen (PSA), Science of health care delivery

Contact Us · Privacy Policy